Developer docs
API playgroundTry for free, no card

Search company profiles

Msd In The Uk

Full company profile

uuid02lbvg6

Namestring
Msd In The Uk
Legal namestring
Merck Sharp & Dohme (UK) Limited
Websiteurl
msd-uk.com
Company typeenum
Public
Founded yearint
1891
Descriptiontext

MSD in the UK operates as Merck Sharp & Dohme (UK) Limited, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK, headquartered in Rahway, NJ). The UK entity develops, supplies, and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious diseases, cardiovascular, immunology, and endocrinology, alongside a separate MSD Animal Health UK division covering veterinary pharmaceuticals. Go-to-market is enterprise field sales directed at NHS trusts, Cancer Alliances, Clinical Commissioning Groups, and primary-care networks, supplemented by community pharmacy distribution for prescription products and veterinary channels for animal health.

The company's commercial engine is NHS pathway development: collaborative working arrangements with named trusts such as The Christie, Oxford University Hospitals, Bradford Teaching Hospitals, The Clatterbridge Cancer Centre, NHS Lothian, and NHS Tayside have produced measurable outcomes in breast, lung, bladder, ovarian, endometrial, renal, head & neck, and triple-negative breast cancer pathways. A parallel grants programme (18 projects in 2025) and patient-organisation partnerships (Body & Soul, Orchid, Roy Castle Lung Cancer Foundation, The Eve Appeal) extend reach into health-equity, awareness, and community-care segments. Technology stack includes MSD Research Labs (MRL) AI agent infrastructure at the London Bioscience Innovation Centre (King's Cross), the NextGen MDT digital solution co-developed with Axana for lung-cancer multidisciplinary team meetings, and an AI receptionist tool deployed with the North Central London Cancer Alliance that delivered a 160% uplift in cervical-screening bookings.

Revenue mechanics are anchored on prescription pharmaceutical and vaccine sales reimbursed through NHS commissioning frameworks, supplemented by animal-health wholesale and non-revenue philanthropic grant flows to patient organisations. Pricing is not publicly disclosed; commercial value is negotiated trust-by-trust via joint-working and pathway-development agreements rather than via transparent list prices. Strategic posture in 2025 is decisively offensive: the announced ~$10 billion acquisition of UK respiratory biopharma Verona Pharma materially extends the cardio-pulmonary pipeline, while MRL investment, AI-mediated care products, and talent programmes (Top Employer UK/Europe for seven consecutive years; 21,500 global EBRG participants across ten groups) signal sustained reinvestment into differentiated capability rather than defensive restructuring.

Short descriptiontext

MSD in the UK is Merck Sharp & Dohme (UK) Limited, the British subsidiary of Merck & Co., Inc., supplying prescription medicines, vaccines, biologic therapies, and animal-health products to NHS trusts, Cancer Alliances, and patient organisations through enterprise field sales and pathway-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, human vaccines, biologic therapies, animal health products, oncology medicines
Industry4 codes
PRIMARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYHLAMAEAG
Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAIAEAH
Veterinary Vaccines
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Veterinary Services54194
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Medicines
TypeOthers
Description

MSD generates revenue through the sale of prescription medicines for human health, including treatments for oncology, immunology, infectious diseases, and other therapeutic areas.

msd-uk.com
2Vaccines
TypeOthers
Description

MSD develops and sells vaccines for the prevention of diseases.

msd-uk.com
3Animal Health Products
TypeOthers
Description

MSD Animal Health, a division of Merck & Co., Inc., offers veterinary pharmaceuticals, vaccines, and health management solutions for veterinarians, farmers, pet owners, and governments. The division operates in more than 150 countries.

msd-uk.com
4Grants and Donations
TypeOthers
Description

MSD provides arm's length financial grants to eligible healthcare and patient organisations to support projects including educational initiatives, local community support, and advocacy projects. This is a philanthropic programme rather than revenue-generating.

msd-uk.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1MSD Animal Health
Description

Global animal health business unit offering veterinary pharmaceuticals, vaccines, and health management solutions

msd-uk.com
+4 more records
Core offering1 text field

MSD in the UK develops, manufactures, and supplies prescription medicines, vaccines, and biologic therapies for human health across therapeutic areas including oncology, infectious diseases, cardiovascular, and endocrinology. The company also offers veterinary pharmaceuticals and animal health management solutions through its MSD Animal Health division operating in over 150 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 160% increase in cervical screening booking rate through AI receptionist tool partnership
+6 more records
Product overview1 text field

MSD in the UK is a global healthcare company operating as a trading name of Merck & Co., Inc. The company delivers innovative health solutions through its core products: prescription medicines, vaccines, and biologic therapies. A key division is MSD Animal Health, offering veterinary pharmaceuticals and vaccines. Beyond pharmaceutical products, MSD operates patient-focused initiatives including MSD for Mothers (maternal health), the Defend Your Tomorrow cervical cancer awareness campaign, patient engagement programmes, and grant funding for healthcare and patient organisations. The company also maintains collaborative working partnerships with NHS organisations for pathway development in oncology and vaccines. The portfolio functions as an integrated healthcare ecosystem combining pharmaceutical products with patient support, awareness campaigns, and NHS partnerships to improve health outcomes.

Product and service4 records
1Prescription Medicines
CategoryPrescription Pharmaceuticals
Description

Innovative prescription medicines targeting challenging human diseases across therapeutic areas including oncology, immunology, and infectious diseases, supplied to NHS trusts, hospitals, and healthcare organisations across the UK.

2Vaccines
CategoryVaccines
Description

Vaccine products developed for the prevention of diseases, distributed globally through NHS commissioning frameworks, community pharmacies, and public health programmes.

3Biologic Therapies
CategoryBiologic Therapies
Description

Biologic therapies offered as part of MSD's innovative health solutions portfolio for human health, targeting complex disease areas.

4MSD Animal Health Products
CategoryAnimal Health Pharmaceuticals
Description

Veterinary pharmaceuticals, vaccines, and health management solutions offered to veterinarians, farmers, pet owners, and governments, operating in more than 150 countries.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

UK White Ribbon Alliance became an MSD for Mothers Grant Recipient, expanding the Free From Harm training to equip 2,000 maternity care providers to prevent obstetric violence and improve outcomes through trauma-informed, equity-centred care.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

MSD's LEAD UK EBRG collaborates with Eli Lilly's embRACE network to host the annual Health Equity hackathon, bringing together undergraduate students to propose innovative solutions to health equity challenges.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-01
Description

Health technology company partnering with MSD and 12 lung cancer clinicians across Europe to develop the NextGen MDT programme - a digital solution to integrate patient information for multidisciplinary team meetings, speeding up lung cancer care.

Strategic tierCoreTypeOthersAnnounced on2025-07-01
Description

UK-based biopharmaceutical company specialising in respiratory diseases that MSD agreed to acquire for approximately $10 billion ($107 per ADS) in July 2025. The acquisition strengthens MSD's innovative pipeline of cardio-pulmonary treatments.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-02-01
Description

MSD partnered with Arsenal FC for the Defend Your Tomorrow® cervical cancer awareness campaign. The partnership leverages Arsenal Women's football team reach to engage communities and individuals across the UK in public health messaging. Activities include matchday takeovers at Emirates Stadium reaching over 55,000 fans.

6The Eve Appeal
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

UK gynaecological cancer charity providing advisory services and feedback on campaign content for the Defend Your Tomorrow® campaign. MSD reimburses The Eve Appeal for these services while allowing the charity to maintain independence.

msd-uk.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Charity receiving MSD grant funding for Positive Parents Place initiative supporting HIV-positive migrant, asylum-seeker and refugee mothers with workshops, therapies, and advocacy initiatives. Over 228 mothers benefited.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Charity receiving MSD funding for targeted awareness campaign on testicular cancer, reaching over 880,000 people through engaging social media content and promoting early detection.

9Positive East
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

East London-based charity dedicated to supporting people living with and affected by HIV. MSD UK Rainbow Alliance EBRG volunteers support Positive East's RED RUN event and community initiatives.

msd-uk.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership with Roy Castle Lung Cancer Foundation to develop support materials for lung cancer carers, including the 'How can I support my loved one with Lung Cancer?' booklet providing insights from patient and carer volunteers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership integrating an AI receptionist tool for cervical screening, resulting in 160% increase in booking rates and administrative time savings, earning national recognition for digital excellence.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD collaborates with multiple NHS trusts and Cancer Alliances on Pathway Development Programmes and Joint Working arrangements. Partners include Belfast Health and Social Care Trust, Bradford Teaching Hospitals, The Christie NHS Foundation Trust, Oxford University Hospitals, NHS Lothian, The Clatterbridge Cancer Centre, South Yorkshire and Bassetlaw Cancer Alliance, NHS Tayside, and University College London Hospitals.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD is a member of PIF and has achieved the PIF Trusted Information Creator accreditation, demonstrating commitment to accurate and accessible health information.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD is a member of PSCI, an industry collaboration supporting principles for responsible supply chain management for ethics, human rights, health and safety, environment, and related governance.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD is a member of BSR's Human Rights Working Group, a global cross-industry network focused on human rights challenges and implementing UN Guiding Principles on Business and Human Rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD is a signatory to the UN Global Compact, committed to advancing the 10 principles on human rights, labour, environment, and anti-corruption, and the UN Sustainable Development Goals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global pharmaceutical peer with oncology, vaccines, and biologics portfolios, selling directly into NHS trusts and hospitals across the UK. Operates UK enterprise field sales with comparable pathway partnership models targeting the same prescribers and clinical commissioning groups.

2Bristol-Myers Squibb
TypeDirect peer
Description

Specialty biopharma peer focused on oncology, immunology and cardiovascular therapies with UK field sales. Participates in NHS pathway development (notably in immuno-oncology) and competes directly with MSD's oncology franchise for NHS commissioning share.

TypeDirect peer
Description

Global pharmaceutical peer with prescription medicines spanning oncology, cardiovascular, and immunology therapeutic areas. Operates UK subsidiary selling through enterprise field sales to NHS trusts, comparable therapeutic coverage and similar NHS partnership models.

TypeDirect peer
Description

Global pharma peer with heavy oncology and biologic therapy portfolio overlapping MSD's human health pipeline. Sells to NHS trusts through UK field sales and engages in pathway development for cancer care, mirroring MSD's NHS joint-working approach.

TypeDirect peer
Description

Global pharmaceutical peer with prescription medicines and vaccines, including specialty oncology and immunology products distributed through NHS channels. Operates UK enterprise field sales targeting NHS trusts and Cancer Alliances in a directly comparable model.

TypeDirect peer
Description

UK-headquartered peer with strong vaccines, specialty medicines, and HIV portfolios distributed via NHS sales teams. Operates a UK subsidiary with comparable headcount and works on NHS pathway development programmes, directly competing with MSD's oncology and vaccine offerings.

TypeDirect peer
Description

UK-headquartered global pharmaceutical company with comparable oncology, vaccines, and biologics portfolios sold into NHS customers. Like MSD UK, it operates enterprise field sales to NHS trusts, runs joint working partnerships, and lists a UK trading entity with significant employee base.

TypeDirect peer
Description

Global pharmaceutical peer with prescription medicines and animal health division (animal health operates in 150+ countries), in both human pharma and veterinary channels comparable to MSD's and MSD Animal Health's dual footprint.

TypeDirect peer
Description

Specialty biopharma peer with oncology, immunology and biologic therapies targeting NHS prescribers. Operates UK enterprise field sales with comparable pathway development programmes in cancer and chronic disease management.

TypeDirect peer
Description

Global pharmaceutical peer with prescription medicines in oncology, endocrinology, and immunology. Co-hosts the MSD Health Equity Hackathon via the embRACE EBRG, indicating overlapping UK employee engagement and patient access programmes targeting NHS prescribers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Msd In The Uk

Pharmaceuticalsmsd-uk.com

MSD in the UK is Merck Sharp & Dohme (UK) Limited, the British subsidiary of Merck & Co., Inc., supplying prescription medicines, vaccines, biologic therapies, and animal-health products to NHS trusts, Cancer Alliances, and patient organisations through enterprise field sales and pathway-development partnerships.

What Msd In The Uk does

MSD in the UK operates as Merck Sharp & Dohme (UK) Limited, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK, headquartered in Rahway, NJ). The UK entity develops, supplies, and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious diseases, cardiovascular, immunology, and endocrinology, alongside a separate MSD Animal Health UK division covering veterinary pharmaceuticals. Go-to-market is enterprise field sales directed at NHS trusts, Cancer Alliances, Clinical Commissioning Groups, and primary-care networks, supplemented by community pharmacy distribution for prescription products and veterinary channels for animal health.

The company's commercial engine is NHS pathway development: collaborative working arrangements with named trusts such as The Christie, Oxford University Hospitals, Bradford Teaching Hospitals, The Clatterbridge Cancer Centre, NHS Lothian, and NHS Tayside have produced measurable outcomes in breast, lung, bladder, ovarian, endometrial, renal, head & neck, and triple-negative breast cancer pathways. A parallel grants programme (18 projects in 2025) and patient-organisation partnerships (Body & Soul, Orchid, Roy Castle Lung Cancer Foundation, The Eve Appeal) extend reach into health-equity, awareness, and community-care segments. Technology stack includes MSD Research Labs (MRL) AI agent infrastructure at the London Bioscience Innovation Centre (King's Cross), the NextGen MDT digital solution co-developed with Axana for lung-cancer multidisciplinary team meetings, and an AI receptionist tool deployed with the North Central London Cancer Alliance that delivered a 160% uplift in cervical-screening bookings.

Revenue mechanics are anchored on prescription pharmaceutical and vaccine sales reimbursed through NHS commissioning frameworks, supplemented by animal-health wholesale and non-revenue philanthropic grant flows to patient organisations. Pricing is not publicly disclosed; commercial value is negotiated trust-by-trust via joint-working and pathway-development agreements rather than via transparent list prices. Strategic posture in 2025 is decisively offensive: the announced ~$10 billion acquisition of UK respiratory biopharma Verona Pharma materially extends the cardio-pulmonary pipeline, while MRL investment, AI-mediated care products, and talent programmes (Top Employer UK/Europe for seven consecutive years; 21,500 global EBRG participants across ten groups) signal sustained reinvestment into differentiated capability rather than defensive restructuring.

Msd In The Uk firmographics

Firmographics
Name
Msd In The Uk
Legal name
Merck Sharp & Dohme (UK) Limited
Website
https://msd-uk.com
Company type
Public
Founded year
1891
Operating status
Operating
Headcount range
251–500 employees
Short description
MSD in the UK is Merck Sharp & Dohme (UK) Limited, the British subsidiary of Merck & Co., Inc., supplying prescription medicines, vaccines, biologic therapies, and animal-health products to NHS trusts, Cancer Alliances, and patient organisations through enterprise field sales and pathway-development partnerships.
Ownership category
akta.pro rank

Msd In The Uk industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYHLAMAEAG
Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAIAEAH
Veterinary Vaccines

Keywords

  • Prescription pharmaceuticals
  • Human vaccines
  • Biologic therapies
  • Animal health products
  • Oncology medicines

Where Msd In The Uk is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Msd In The Uk business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Prescription Medicines: MSD generates revenue through the sale of prescription medicines for human health, including treatments for oncology, immunology, infectious diseases, and other therapeutic areas.
  2. Vaccines: MSD develops and sells vaccines for the prevention of diseases.
  3. Animal Health Products: MSD Animal Health, a division of Merck & Co., Inc., offers veterinary pharmaceuticals, vaccines, and health management solutions for veterinarians, farmers, pet owners, and governments. The division operates in more than 150 countries.
  4. Grants and Donations: MSD provides arm's length financial grants to eligible healthcare and patient organisations to support projects including educational initiatives, local community support, and advocacy projects. This is a philanthropic programme rather than revenue-generating.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Msd In The Uk product offering

Product offering

Core offering

MSD in the UK develops, manufactures, and supplies prescription medicines, vaccines, and biologic therapies for human health across therapeutic areas including oncology, infectious diseases, cardiovascular, and endocrinology. The company also offers veterinary pharmaceuticals and animal health management solutions through its MSD Animal Health division operating in over 150 countries.

Product overview

MSD in the UK is a global healthcare company operating as a trading name of Merck & Co., Inc. The company delivers innovative health solutions through its core products: prescription medicines, vaccines, and biologic therapies. A key division is MSD Animal Health, offering veterinary pharmaceuticals and vaccines. Beyond pharmaceutical products, MSD operates patient-focused initiatives including MSD for Mothers (maternal health), the Defend Your Tomorrow cervical cancer awareness campaign, patient engagement programmes, and grant funding for healthcare and patient organisations. The company also maintains collaborative working partnerships with NHS organisations for pathway development in oncology and vaccines. The portfolio functions as an integrated healthcare ecosystem combining pharmaceutical products with patient support, awareness campaigns, and NHS partnerships to improve health outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • MSD Animal Health: Global animal health business unit offering veterinary pharmaceuticals, vaccines, and health management solutions
  • Defend Your Tomorrow
  • MSD for Mothers
  • MSD UK Grants Programme
  • Red Chair Initiative

Products and services

  • Prescription Medicines Innovative prescription medicines targeting challenging human diseases across therapeutic areas including oncology, immunology, and infectious diseases, supplied to NHS trusts, hospitals, and healthcare organisations across the UK.
  • Vaccines Vaccine products developed for the prevention of diseases, distributed globally through NHS commissioning frameworks, community pharmacies, and public health programmes.
  • Biologic Therapies Biologic therapies offered as part of MSD's innovative health solutions portfolio for human health, targeting complex disease areas.
  • MSD Animal Health Products Veterinary pharmaceuticals, vaccines, and health management solutions offered to veterinarians, farmers, pet owners, and governments, operating in more than 150 countries.

Quantifiable outcome

  • 160% increase in cervical screening booking rate through AI receptionist tool partnership
  • +6 more outcomes

Companies that use Msd In The Uk

Customer profile

Named customers12 records

Segments5 records

Ideal customer profiles3 records

Msd In The Uk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Msd In The Uk partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • White Ribbon AlliancecoreStrategic or Co-development Partner · 1 May 2026UK White Ribbon Alliance became an MSD for Mothers Grant Recipient, expanding the Free From Harm training to equip 2,000 maternity care providers to prevent obstetric violence and improve outcomes through trauma-informed, equity-centred care.
  • Eli Lilly (embRACE)coreStrategic or Co-development Partner · 1 September 2025MSD's LEAD UK EBRG collaborates with Eli Lilly's embRACE network to host the annual Health Equity hackathon, bringing together undergraduate students to propose innovative solutions to health equity challenges.
  • AxanacoreTechnology or Integration · 1 July 2025Health technology company partnering with MSD and 12 lung cancer clinicians across Europe to develop the NextGen MDT programme - a digital solution to integrate patient information for multidisciplinary team meetings, speeding up lung cancer care.
  • Verona PharmacoreOthers · 1 July 2025UK-based biopharmaceutical company specialising in respiratory diseases that MSD agreed to acquire for approximately $10 billion ($107 per ADS) in July 2025. The acquisition strengthens MSD's innovative pipeline of cardio-pulmonary treatments.
  • Arsenal Football ClubcoreGTM or Marketing Partner · 1 February 2025MSD partnered with Arsenal FC for the Defend Your Tomorrow® cervical cancer awareness campaign. The partnership leverages Arsenal Women's football team reach to engage communities and individuals across the UK in public health messaging. Activities include matchday takeovers at Emirates Stadium reaching over 55,000 fans.
  • The Eve AppealcoreStrategic or Co-development Partner · 1 February 2025UK gynaecological cancer charity providing advisory services and feedback on campaign content for the Defend Your Tomorrow® campaign. MSD reimburses The Eve Appeal for these services while allowing the charity to maintain independence.
  • Body & SoulminorStrategic or Co-development Partner · 1 January 2025Charity receiving MSD grant funding for Positive Parents Place initiative supporting HIV-positive migrant, asylum-seeker and refugee mothers with workshops, therapies, and advocacy initiatives. Over 228 mothers benefited.
  • OrchidminorStrategic or Co-development Partner · 1 January 2025Charity receiving MSD funding for targeted awareness campaign on testicular cancer, reaching over 880,000 people through engaging social media content and promoting early detection.
  • Positive EastcoreStrategic or Co-development Partner · 1 November 2024East London-based charity dedicated to supporting people living with and affected by HIV. MSD UK Rainbow Alliance EBRG volunteers support Positive East's RED RUN event and community initiatives.
  • Roy Castle Lung Cancer FoundationcoreStrategic or Co-development Partner · 1 January 2024Partnership with Roy Castle Lung Cancer Foundation to develop support materials for lung cancer carers, including the 'How can I support my loved one with Lung Cancer?' booklet providing insights from patient and carer volunteers.
  • North Central London Cancer AlliancecoreStrategic or Co-development Partner · 1 January 2024Partnership integrating an AI receptionist tool for cervical screening, resulting in 160% increase in booking rates and administrative time savings, earning national recognition for digital excellence.
  • NHS Trusts and Cancer AlliancescoreStrategic or Co-development PartnerMSD collaborates with multiple NHS trusts and Cancer Alliances on Pathway Development Programmes and Joint Working arrangements. Partners include Belfast Health and Social Care Trust, Bradford Teaching Hospitals, The Christie NHS Foundation Trust, Oxford University Hospitals, NHS Lothian, The Clatterbridge Cancer Centre, South Yorkshire and Bassetlaw Cancer Alliance, NHS Tayside, and University College London Hospitals.
  • Patient Information Forum (PIF)coreStrategic or Co-development PartnerMSD is a member of PIF and has achieved the PIF Trusted Information Creator accreditation, demonstrating commitment to accurate and accessible health information.
  • Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development PartnerMSD is a member of PSCI, an industry collaboration supporting principles for responsible supply chain management for ethics, human rights, health and safety, environment, and related governance.
  • BSR (Business for Social Responsibility)coreStrategic or Co-development PartnerMSD is a member of BSR's Human Rights Working Group, a global cross-industry network focused on human rights challenges and implementing UN Guiding Principles on Business and Human Rights.
  • United Nations Global CompactcoreStrategic or Co-development PartnerMSD is a signatory to the UN Global Compact, committed to advancing the 10 principles on human rights, labour, environment, and anti-corruption, and the UN Sustainable Development Goals.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Msd In The Uk competitors and assessment

Company assessment

Direct peers

  • Pfizer: Global pharmaceutical peer with oncology, vaccines, and biologics portfolios, selling directly into NHS trusts and hospitals across the UK. Operates UK enterprise field sales with comparable pathway partnership models targeting the same prescribers and clinical commissioning groups.
  • Bristol-Myers Squibb: Specialty biopharma peer focused on oncology, immunology and cardiovascular therapies with UK field sales. Participates in NHS pathway development (notably in immuno-oncology) and competes directly with MSD's oncology franchise for NHS commissioning share.
  • Novartis: Global pharmaceutical peer with prescription medicines spanning oncology, cardiovascular, and immunology therapeutic areas. Operates UK subsidiary selling through enterprise field sales to NHS trusts, comparable therapeutic coverage and similar NHS partnership models.
  • Roche: Global pharma peer with heavy oncology and biologic therapy portfolio overlapping MSD's human health pipeline. Sells to NHS trusts through UK field sales and engages in pathway development for cancer care, mirroring MSD's NHS joint-working approach.
  • Sanofi: Global pharmaceutical peer with prescription medicines and vaccines, including specialty oncology and immunology products distributed through NHS channels. Operates UK enterprise field sales targeting NHS trusts and Cancer Alliances in a directly comparable model.
  • GSK: UK-headquartered peer with strong vaccines, specialty medicines, and HIV portfolios distributed via NHS sales teams. Operates a UK subsidiary with comparable headcount and works on NHS pathway development programmes, directly competing with MSD's oncology and vaccine offerings.
  • AstraZeneca: UK-headquartered global pharmaceutical company with comparable oncology, vaccines, and biologics portfolios sold into NHS customers. Like MSD UK, it operates enterprise field sales to NHS trusts, runs joint working partnerships, and lists a UK trading entity with significant employee base.
  • Bayer UK: Global pharmaceutical peer with prescription medicines and animal health division (animal health operates in 150+ countries), in both human pharma and veterinary channels comparable to MSD's and MSD Animal Health's dual footprint.
  • AbbVie: Specialty biopharma peer with oncology, immunology and biologic therapies targeting NHS prescribers. Operates UK enterprise field sales with comparable pathway development programmes in cancer and chronic disease management.
  • Eli Lilly: Global pharmaceutical peer with prescription medicines in oncology, endocrinology, and immunology. Co-hosts the MSD Health Equity Hackathon via the embRACE EBRG, indicating overlapping UK employee engagement and patient access programmes targeting NHS prescribers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

Msd In The Uk social profiles

Digital presence

Msd In The Uk compliance and trust

Trust signal

Compliance3 records

Msd In The Uk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Msd In The Uk leadership team

Management profile

Number of profiles

Profiles8 records

Msd In The Uk subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Msd In The Uk funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Msd In The Uk M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Msd In The Uk

What does Msd In The Uk do?

MSD in the UK develops, manufactures, and supplies prescription medicines, vaccines, and biologic therapies for human health across therapeutic areas including oncology, infectious diseases, cardiovascular, and endocrinology. The company also offers veterinary pharmaceuticals and animal health management solutions through its MSD Animal Health division operating in over 150 countries.

Is Msd In The Uk a public or private company?

Msd In The Uk is a public company. It is classified as corporate owned and is currently operating.

When was Msd In The Uk founded?

Msd In The Uk was founded in 1891. It employs 251 to 500 people.

Where is Msd In The Uk based?

Msd In The Uk is headquartered in London, United Kingdom, in the Europe region.

How does Msd In The Uk make money?

Four revenue lines are on record. Prescription Medicines are the primary driver. The others are vaccines, animal Health Products and grants and Donations.

Who are Msd In The Uk's main competitors?

Direct peers on record are Pfizer, Bristol-Myers Squibb, Novartis, Roche, Sanofi, GSK, AstraZeneca, Bayer UK, AbbVie and Eli Lilly.

Does Msd In The Uk have an API?

No public API is recorded for Msd In The Uk.

What industry is Msd In The Uk in?

Msd In The Uk's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAMAKAM, Vaccine R&D, Clinical/Field Trials & Regulatory Affairs, with a secondary code of HLAMAEAG, Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals